Vaccination Policy in Kidney Transplantation

Pre-Transplant Vaccination Strategy

Kidney transplant recipients should receive all approved inactivated vaccines according to standard schedules, but live vaccines must be avoided post-transplant, with most vaccinations delayed until 6 months after transplantation except for influenza vaccine which can be given as early as 1 month post-transplant, as recommended by the American Society of Transplantation 1
Live attenuated vaccines should be given at least 4 weeks prior to transplant to ensure safety, according to the Infectious Diseases Society of America 2

Avoid all vaccinations (except influenza) during the first 6 months post-transplant due to intensified immunosuppression and poor immune response during this period, as stated by the American Society of Transplantation and the Infectious Diseases Society of America 1, 2
Exception: Influenza vaccination can be administered as early as 1 month post-transplant, regardless of immunosuppression status, and should be given annually before influenza season begins, as recommended by the American Society of Transplantation 1
Once patients reach minimal maintenance immunosuppression (typically 2-6 months post-transplant), resume standard age-appropriate inactivated vaccines according to CDC schedules, as advised by the American Society of Transplantation and the Infectious Diseases Society of America 1, 2

Pneumococcal vaccines: PCV13 followed by PPSV23 at least 8 weeks later, as recommended by the Infectious Diseases Society of America 2
Influenza vaccine (inactivated): Annually, starting at 1 month post-transplant, as recommended by the American Society of Transplantation 1
Tetanus-diphtheria-pertussis (Tdap): Per standard adult schedules, as advised by the Infectious Diseases Society of America 3
Hepatitis B: Ideally vaccinate prior to transplantation using high-dose formulation (40 μg) for dialysis patients, with monitoring of HBsAb titers 6-12 weeks after completing the vaccination series and annual monitoring post-transplant, as recommended by the American Society of Transplantation and the Infectious Diseases Society of America 1, 3

Live vaccines are generally contraindicated in kidney transplant recipients due to risk of vaccine-strain infection in immunosuppressed patients, as stated by the American Society of Transplantation and the Infectious Diseases Society of America 1, 2
Very limited exception: Varicella vaccine may be considered in pediatric renal transplant recipients without evidence of immunity who are on minimal immunosuppression with no recent rejection, though data remain limited, as noted by the Infectious Diseases Society of America 2

Vaccination does not increase risk of transplant organ rejection and should not be withheld due to this concern, as stated by the Infectious Diseases Society of America 2

Rabies infection is almost uniformly fatal (≈ 100 % mortality) in both immunocompetent and immunosuppressed individuals, making prevention the only effective strategy. 4

The rabies vaccine is an inactivated (killed) product, and in solid‑organ transplant recipients it is considered safe, producing only minimal and self‑limited adverse effects. 4
Inactivated vaccines in general are well‑tolerated in transplant patients, with no contraindication despite concurrent immunosuppressive therapy. 4, 5

After a confirmed rabies exposure, transplant recipients should receive an aggressive PEP regimen that includes 4–8 intradermal doses of human diploid‑cell inactivated rabies vaccine. 4
PEP must be combined with rabies immune globulin administered at the time of the first vaccine dose to provide immediate passive immunity. 4

The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines specifically advise rabies vaccination for kidney transplant candidates and recipients who have elevated occupational or travel‑related risk. 5, 6, 7
Optimal timing for PrEP is before transplantation, when the immune system can mount a more robust antibody response. 4
If vaccination is performed after transplantation, it should be delayed until at least 6 months post‑transplant and when the patient is on minimal maintenance immunosuppression, except in emergency exposure situations. 5

Do not withhold rabies vaccine after exposure in transplant patients, regardless of immunosuppression status, because the risk of death from rabies outweighs theoretical vaccine concerns. 4
Do not mistake the rabies vaccine for a live vaccine; it is inactivated and therefore safe for immunocompromised hosts. 4